Interim report, foreign filer
Open the filing on sec.gov
Clearmind Medicine Inc. (CMND)
Nasdaq: CMND · Pharmaceutical Preparations · Vancouver, British Columbia, CA · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenuen/a
Net income-$3.9M+26.6%
Earnings per share$-30.35+55.2%
Operating cash flow-$4.7M+2.6%
Cash$3.9M-40.3%
Debtn/a
Shareholders’ equity$1.2M-61.6%
Shares, diluted127,093+64.0%
Return on equity-323.4%
The recordfrom its filings
Filings in 2026100
Newest filingNov 10 · 6-K
Annual reportJan 20, 2026
Quarterly reportn/a
Next report due20-F by Feb 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted5
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Large holder notice
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.